STOCK TITAN
  1. Home
  2. Sec-filings
  3. CTNM
  4. [Form 4] Contineum Therapeutics, Inc. Insider Trading Activity

Contineum Therapeutics (CTNM) grants stock options to CSO and spouse

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Contineum Therapeutics granted stock options to Chief Scientific Officer Lorrain Daniel S. on January 30, 2026 under its 2024 Equity Incentive Plan. The award covers options to buy 160,000 shares of Class A common stock at an exercise price of $14.26 per share, expiring on January 29, 2036. These options vest in equal monthly installments over 48 months, conditioned on the executive’s continued service.

An additional grant of stock options to purchase 6,500 shares of Class A common stock at $14.26 per share was made in connection with the continuous service of the executive’s spouse at the company. These options have the same 48‑month monthly vesting schedule and are reported as indirectly owned through the spouse.

Positive

  • None.

Negative

  • None.
Insider Lorrain Daniel S.
Role Chief Scientific Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 160,000 $0.00 --
Grant/Award Stock Option (right to buy) 6,500 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 160,000 shares (Direct); Stock Option (right to buy) — 6,500 shares (Indirect, By Spouse)
Footnotes (1)
  1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's spouse's continuous service.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lorrain Daniel S.
(Last) (First) (Middle)
3565 GENERAL ATOMICS COURT, SUITE 200
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $14.26 01/30/2026 A 160,000 (1) 01/29/2036 Class A Common Stock 160,000 $0 160,000 D
Stock Option (right to buy) $14.26 01/30/2026 A 6,500 (2) 01/29/2036 Class A Common Stock 6,500 $0 6,500 I By Spouse
Explanation of Responses:
1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.
2. Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's spouse's continuous service.
/s/ Peter Slover, Attorney-in-Fact 01/30/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What stock options were granted to CTNM Chief Scientific Officer Lorrain Daniel S.?

The Chief Scientific Officer received stock options for 160,000 shares of Class A common stock at an exercise price of $14.26 per share. These options were granted under the 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, contingent on continued service.

What is the vesting schedule for the CTNM stock options reported by Lorrain Daniel S.?

Both the 160,000 and 6,500 stock option grants vest in equal monthly installments over 48 months. Vesting of the primary grant depends on the Chief Scientific Officer’s continuous service, while vesting of the spouse-related grant depends on the spouse’s continued employment at the company.

When do the Contineum Therapeutics options held by Lorrain Daniel S. expire?

The reported stock options, including those associated with the spouse, have an expiration date of January 29, 2036. This means they can be exercised at the $14.26 exercise price any time after vesting and before that expiration date, subject to plan and service conditions.

Are the CTNM options reported by Lorrain Daniel S. held directly or indirectly?

The 160,000 stock options are reported as held directly by the Chief Scientific Officer. The additional 6,500 options are reported as indirectly owned, described as held “By Spouse,” reflecting that they relate to the spouse’s continuous service at Contineum Therapeutics.

Under which plan were the CTNM options for Lorrain Daniel S. granted?

All reported options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan. The plan governs key terms such as vesting in equal monthly installments over 48 months, continuous service requirements, the $14.26 exercise price, and the January 29, 2036 expiration date.